Eli Lilly and Co. has initiated additional legal actions against compounding pharmacies, alleging the unauthorized sale of imitation versions of its weight loss and diabetes drugs. The lawsuits, filed in federal courts in New Jersey and Delaware, target two online pharmacies that are purportedly misleading consumers by offering counterfeit products.
This legal maneuver is the latest development in Eli Lilly’s ongoing efforts to protect its pharmaceutical patents and market share. More detailed information about these lawsuits and the implications for the pharmaceutical industry can be found in the original report by Law360.